152 related articles for article (PubMed ID: 15563771)
1. Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening.
Gattellari M; Ward JE
J Med Screen; 2004; 11(4):165-9. PubMed ID: 15563771
[TBL] [Abstract][Full Text] [Related]
2. Does 'peer coaching' increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial.
Gattellari M; Donnelly N; Taylor N; Meerkin M; Hirst G; Ward JE
Fam Pract; 2005 Jun; 22(3):253-65. PubMed ID: 15824055
[TBL] [Abstract][Full Text] [Related]
3. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
[TBL] [Abstract][Full Text] [Related]
5. A community-based randomised controlled trial of three different educational resources for men about prostate cancer screening.
Gattellari M; Ward JE
Patient Educ Couns; 2005 May; 57(2):168-82. PubMed ID: 15911190
[TBL] [Abstract][Full Text] [Related]
6. Predictors of prostate cancer screening among health fair participants.
Chiu BC; Anderson JR; Corbin D
Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
[TBL] [Abstract][Full Text] [Related]
7. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
8. Self-reported prevalence of prostate-specific antigen testing in South Australia: a community study.
Pinnock CB; Weller DP; Marshall VR
Med J Aust; 1998 Jul; 169(1):25-8. PubMed ID: 9695698
[TBL] [Abstract][Full Text] [Related]
9. GP and patient predictors of PSA screening in Australian general practice.
Gattellari M; Young JM; Ward JE
Fam Pract; 2003 Jun; 20(3):294-303. PubMed ID: 12738699
[TBL] [Abstract][Full Text] [Related]
10. Behavioral associations between prostate and colon cancer screening.
Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
Ito K
Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
[TBL] [Abstract][Full Text] [Related]
12. A national survey of medical students' beliefs and knowledge in screening for prostate cancer.
Marcella S; Delnevo CD; Coughlin SS
J Gen Intern Med; 2007 Jan; 22(1):80-5. PubMed ID: 17351844
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
14. What influences men's decision to have a prostate-specific antigen test? A qualitative study.
Rai T; Clements A; Bukach C; Shine B; Austoker J; Watson E
Fam Pract; 2007 Sep; 24(4):365-71. PubMed ID: 17644829
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
16. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
17. Intention to test for prostate cancer.
Berglund G; Nilsson S; Nordin K
Eur J Cancer; 2005 May; 41(7):990-7. PubMed ID: 15862747
[TBL] [Abstract][Full Text] [Related]
18. Trends in prostate-specific antigen testing from 1995 through 2004.
Farwell WR; Linder JA; Jha AK
Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173
[TBL] [Abstract][Full Text] [Related]
19. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
